Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/dual-hormone-and-adjunct-therapy-devices-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Diabetes TechnologyDual hormone and adjunct therapy device patents: mapping the filers, the claim clusters, and the open ground
- Filing peaked in 2022 at 18 records and the 2021-to-2024 span shows a -100% swing, though 2025-2026 counts are still filling in as publications lag behind filing.
- A61M and G16H dominate the claim space at 92.9% and 76.2% of the 42 records in scope respectively, leaving image processing and positive-displacement pump mechanics comparatively open.
- The ranked leader holds 20 records against a fifth-place assignee with just 1, in a ranking of five companies total rather than a broad field of filers.
42
Published Records
-100%
Filing Growth 2021→2024
US
Leading Jurisdiction
5
Active Filers Ranked
Filing growth compares 2021 (10 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview
What this landscape covers
This review covers 42 published patent records matched against dual hormone delivery and glucagon delivery devices, cross-referenced with dosing algorithms, dual chamber pump mechanics, cartridge design, and clinical benefit claims. The scope spans filings from 2015 through the 2026-07-31 cut-off, with 2025 and later years understated because publication typically lags filing by around 18 months.
Records here sit at the intersection of drug administration hardware and the software layer that governs dosing decisions, which is why healthcare informatics claims appear almost as often as the physical delivery devices themselves.
Filing activity and technology composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Dual Hormone and Adjunct Therapy Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data
Filing trend and technology mix
The two views below cover the same 42 records from different angles: one tracks when filings were published, the other tracks which IPC subclasses those filings carry.
Filing trend, 2017-2026
Filings rose to a peak of 18 in 2022, then the evidenced 2021-to-2024 window shows a -100% change. Treat 2025 and 2026 as incomplete rather than as evidence of a slowdown, since publication lag means recent filings have not all surfaced yet.
Technology composition by IPC subclass
A61M (devices for body fluids) appears in 92.9% of the 42 records and G16H (healthcare informatics) in 76.2%, confirming that most filings pair a physical delivery mechanism with a software dosing layer. Because records can carry multiple classes, these shares add up to well over 100% and should be read as claim density, not as a partition of the field.
Shares are the percentage of the 42 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Dual Hormone and Adjunct Therapy Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Dual Hormone and Adjunct Therapy Devices with Eureka
This page is one run against one query. Ask Eureka your own question about dual hormone and adjunct therapy devices and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Most-cited records and a representative filing
Representative Filing
Wearable Drug Infusion Device (US20230355869A1, SFC Fluidics)
SFC FLUIDICS, INC.
A low dose drug delivery pod comprised of a reciprocating pump, an active valve set, and, in some embodiments, a dispense confirmation sensor. The active valve set uses mechanical interference so both the inlet and outlet valve must close before either one opens, ensuring at least one valve stays closed at all times. The dispense confirmation sensor is a flow-based detection system that gives rapid feedback on whether an individual dose was delivered.Filed by SFC Fluidics, published 2023-11-09.
Highest-cited records in the searched corpus
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20210345952A1 | Controlling operation of drug administration devices using surgical hubs | 84 |
| 2 | US12051495B2 | Patient monitoring using drug administration devices | 65 |
| 3 | US20220189604A1 | Glucose level control system with therapy customization | 26 |
| 4 | US20210350896A1 | Patient monitoring using drug administration devices | 23 |
| 5 | US20220188388A1 | Ambulatory medicament pump with safe access control | 16 |
| 6 | US20220189602A1 | Ambulatory medicament pump with safe access control | 14 |
| 7 | WO2021059211A1 | Drug delivery adjustment | 10 |
| 8 | US20220184305A1 | Modular blood glucose control systems | 7 |
| 9 | US20220184306A1 | Ambulatory medicament pump with safe access control | 6 |
| 10 | US20220189603A1 | Medicament pumps and control systems for managing glucose control therapy data of a subject | 5 |
Citation counts favour older records simply because they have had more time to accumulate citations within the searched set; treat them as a signal of influence on later filings, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Dual Hormone and Adjunct Therapy Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing decision
Three patterns matter more than the raw counts: where claim density sits, what the citation leaders actually protect, and how narrow the ranked field of assignees really is.
Claim Density
92.9% of records
carry an A61M class
Delivery hardware is the densest claim zone
Nearly every record in scope touches A61M (devices for body fluids), which means basic pump, cartridge, and infusion-path mechanics are heavily claimed. New hardware entrants should expect to design around, not around, existing valve and cartridge architectures.
Based on IPC subclass shares across 42 records.
Software Layer
76.2% of records
carry a G16H class
Dosing algorithms are claimed almost as densely as hardware
Healthcare informatics claims sit close behind delivery hardware in frequency, confirming that dosing logic and therapy customization are treated as core IP, not as an afterthought to the pump.
Based on IPC subclass shares across 42 records.
Citation Leaders
84 citations
on the top-cited record
Surgical-hub-controlled administration draws the most follow-on citation
The most-cited record concerns controlling drug administration devices using surgical hubs, with the next several highest-cited records also centred on patient monitoring during administration rather than on the dosing algorithm itself.
Citation counts favour earlier-published records; read as influence, not current relevance.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to dual hormone and adjunct therapy devices, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Dual Hormone and Adjunct Therapy Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who holds the claim space
The assignee ranking returned for this topic covers five companies, from a leader with 20 records down to a fifth-place holder with a single record. That is the entire ranked field the data endpoint returns for this search, not a shortlist trimmed from a larger set.
Leader
20 records
ranked leader
One assignee holds the largest single block
The leading assignee's filings anchor much of the drug administration and patient monitoring citation activity seen in the most-cited records, suggesting its portfolio sets much of the reference baseline for later filers.
Recent-year momentum for this assignee shows 0 filings in the latest tracked year, consistent with publication lag.
Device Specialist
Wearable pod claims
SFC Fluidics
A smaller filer holds a distinct mechanical niche
SFC Fluidics' representative filing on active valve interference and dispense confirmation sensing shows a narrower but technically specific claim position in wearable low-dose delivery pods, separate from the broader administration-and-monitoring cluster.
Representative record: US20230355869A1.
Long Tail
1 record
fifth-ranked assignee
The ranked field thins out quickly past the leader
Filings drop off sharply after the top of the ranking, with the fifth-ranked assignee holding just one record. This is a narrow, concentrated field of named players rather than a broad competitive set.
Ranking covers 5 companies total.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Janssen Pharmaceuticals, Inc. | 0 | -100% |
| Beta Bionics, Inc. | 0 | — |
| SFC Fluidics, Inc. | 0 | — |
| Oregon Health & Science University | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Dual Hormone and Adjunct Therapy Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The trend and composition data point to a field with dense hardware and software claims at the top and thin coverage in a few specific mechanical and imaging niches.
Check freedom-to-operate against the top-cited records
Before committing to a delivery hardware or monitoring architecture, review the surgical-hub-controlled administration and patient monitoring records that draw the highest citation counts in this corpus.
Explore citation network in EurekaProbe the under-claimed branches
Image-based dose confirmation and wireless dual-chamber synchronisation show comparatively low claim density; a first-mover claim drafted narrowly around either could avoid the densest prior art.
Run a white space search in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Dual Hormone and Adjunct Therapy Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
Within this dataset, the assignee ranking covers five companies, with the leading assignee holding 20 of the ranked records and the fifth-ranked holder just 1. This is a narrow, concentrated ranked field rather than a broad competitive landscape, so a new entrant should expect to negotiate around a small number of established portfolios rather than many scattered small filers.
Filing activity peaked in 2022 at 18 records, and the evidenced 2021-to-2024 window shows a -100% change over that span. However, 2025 and 2026 figures are still incomplete because publication typically lags actual filing by about 18 months, so the apparent decline in the most recent years should not be read as the field slowing down.
A61M, the IPC subclass covering devices for body fluids, appears in 92.9% of the 42 records in scope, and G16H, healthcare informatics, appears in 76.2%. That means most filings combine a physical delivery mechanism with software-driven dosing logic, and both layers are claimed densely enough that new filers should expect to search prior art in both categories, not just the hardware.
Positive-displacement pump mechanics (F04B) and image data processing (G06T) show comparatively low claim density at 9.5% and 2.4% of the 42 records respectively, versus over 90% for core delivery hardware. Sub-areas like image-based dose confirmation, wireless dual-chamber synchronisation, and glucagon cartridge stability packaging appear under-claimed relative to the rest of the field, making them worth a closer freedom-to-operate check before drafting.
US20230355869A1, filed by SFC Fluidics, covers a wearable low-dose drug delivery pod built around a reciprocating pump and an active valve set with mechanical interference, so that both the inlet and outlet valve must close before either opens. It also describes a flow-based dispense confirmation sensor that gives rapid feedback on whether an individual dose was delivered. Anyone designing a wearable pod with a similar dual-valve interlock or flow-based confirmation mechanism should review this filing closely before finalising a valve architecture.
Answers are grounded in the same dataset. Derived from a Patsnap search on Dual Hormone and Adjunct Therapy Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Dual Hormone and Adjunct Therapy Devices in depth with Eureka
Go past this page: query the whole dual hormone and adjunct therapy devices corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.